Home › Trials › NCT04080245
Clinical trial No longer in our active list Early Phase 1 Interventional Ages 18 to 50

Investigating immune responses to a flu vaccine

Official title: Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)

Run by University of Alabama at Birmingham · NCT04080245 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study tests how healthy people’s immune systems respond to a flu vaccine to see if it can help protect them better in the long run.

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages18 Years to 50 Years
SexAll
Enrollment18 (estimated)
SponsorUniversity of Alabama at Birmingham
Academic / other
Locations1 site (Birmingham, Alabama)
Trial IDNCT04080245 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are healthy individuals who have not received a flu vaccine in the past year and do not have a history of reactive airway disease or allergies to the vaccines.

Probably not a fit

Patients with a history of reactive airway disease, allergies to LAIV or IIV, or those who do not self-identify as healthy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study examines the immune response of healthy individuals to the Live Attenuated Influenza Vaccine (LAIV) and its potential as a biomarker for long-lasting antibody responses. Participants will receive the LAIV and their immune responses will be assessed, followed by an intramuscular influenza vaccination to evaluate if the initial LAIV provides protective immunity. The research aims to identify specific B cell populations that may indicate effective immune protection after vaccination.

Why it matters

Potential benefit: If successful, this study could help identify biomarkers that predict long-term immunity to influenza, improving vaccination strategies.

How similar studies have gone: While this approach is novel in its specific focus on T-bet expressing B cells, previous studies have shown success in identifying immune responses to influenza vaccines.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Missed getting the flu vaccine in the last year
* No history of reactive airway disease
* No history of allergy to LAIV
* No history of allergy to IIV
* Self-identify as healthy without an immunocompromising condition defined as cancer, autoimmune disease, organ transplant or receipt of steroids.

Exclusion Criteria:

* History of reactive airway disease
* History of allergy to LAIV or IIV
* Do not self-identify as healthy

Where it's running

  • University of Alabama at Birmingham
    Birmingham, Alabama, United States     Recruiting

Study contacts

  • Principal investigator: Anoma Nellore, MD — University of Alabama at Birmingham
  • Study coordinator: Anoma Nellore, MD
  • Email: anellore@uabmc.edu
  • Phone: 2059345191

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Influenza, Human 10University of Alabama at Birmingham 1432
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.